Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Oruka Therapeutics ( (ORKA) ) is now available.
On April 27, 2026, Oruka Therapeutics reported positive interim results from its Phase 2a EVERLAST-A trial of ORKA-001 in moderate-to-severe plaque psoriasis, with 63.5% of treated patients achieving complete skin clearance (PASI 100 and identical IGA 0 rates) at Week 16 versus 4.8% on placebo. Secondary endpoints, including PASI 90 and IGA 0/1, also showed high response rates, and cross-trial comparisons suggested numerically higher skin-clearance outcomes than other IL-23p19 inhibitors, underscoring ORKA-001’s potential competitiveness in the psoriasis biologics market.
The safety profile of ORKA-001 in EVERLAST-A was favorable and similar to placebo, with no serious treatment-emergent adverse events, no discontinuations due to adverse events, and upper respiratory tract infection as the only common adverse event, supporting its tolerability in line with the IL-23p19 class. Updated Phase 1 pharmacokinetic and pharmacodynamic data showed drug levels and IL-23 pathway inhibition sustained for a year after a single 600 mg dose, reinforcing the prospect of once-yearly dosing, while Oruka’s ongoing EVERLAST-A and dose-ranging EVERLAST-B Phase 2b trial—now enrolling about 160 patients with data expected in 2027—could further validate the drug’s long-acting profile and potentially strengthen the company’s competitive position in chronic psoriasis treatment.
The most recent analyst rating on (ORKA) stock is a Buy with a $125.00 price target. To see the full list of analyst forecasts on Oruka Therapeutics stock, see the ORKA Stock Forecast page.
Spark’s Take on ORKA Stock
According to Spark, TipRanks’ AI Analyst, ORKA is a Neutral.
The score is held down primarily by weak financial performance (no revenue, rising losses, and accelerating cash burn), partially offset by a strong balance sheet with very low leverage. Technicals add support due to strong uptrend and positive momentum, though overbought signals reduce conviction. Valuation remains constrained by negative earnings and lack of a dividend.
To see Spark’s full report on ORKA stock, click here.
More about Oruka Therapeutics
Oruka Therapeutics, Inc. is a Nasdaq-listed, clinical-stage biotechnology company focused on developing novel biologic therapies for chronic skin diseases, particularly moderate-to-severe plaque psoriasis. The company is advancing a proprietary portfolio of engineered antibodies, including its lead IL-23p19 monoclonal antibody ORKA-001, aiming to achieve high rates of complete disease clearance with dosing as infrequently as once or twice a year.
Oruka’s market focus centers on dermatologic and inflammatory diseases where long-acting biologics could redefine standards of care and patient convenience. Its programs, built on antibodies engineered by Paragon Therapeutics, target core mechanisms of disease in plaque psoriasis and related conditions, positioning the company within the competitive but fast-growing immuno-dermatology segment.
Average Trading Volume: 758,818
Technical Sentiment Signal: Buy
Current Market Cap: $3.42B
See more data about ORKA stock on TipRanks’ Stock Analysis page.